-
From Anxiety to Hope: Understanding the Adoption of AI Counseling Tools for Anxiety Management
Sep 9, 2025, 16:22 PM -
Incidence and Prevalence of Primary Biliary Cholangitis (PBC) and Cholestatic Pruritus (CP) in Germany: Results From a Statutory Health Insurance (SHI) Claims Analysis
Sep 9, 2025, 16:22 PM -
Budget Impact of the VELYS™ Robotic-Assisted Solution Compared to Manual Procedure in Patients Undergoing Primary Total Knee Arthroplasty in France
Sep 9, 2025, 16:22 PM -
Role of Real-World Evidence (RWE) in Pricing and Reimbursement Decisions for Rare Disease in Health Technology Assessment (HTA) Submissions Across EU4 + UK
Sep 9, 2025, 16:22 PM -
Systematic Literature Review and Bayesian Network Meta-Analysis of Sugemalimab Plus Chemotherapy vs. Other First-Line Treatments for Metastatic Non-Small Cell Lung Cancer Without Sensitizing eGFR, ALK, ROS1, or RET Alterations
Sep 9, 2025, 16:22 PM -
Identification of Real-World Data to Study HAE Unmet Need: A Targeted Literature Review
Sep 9, 2025, 16:22 PM -
The Cost-Effectiveness of Targeted-Release Form (TRF)-Budesonide for the Treatment of Adult Population With Immunoglobulin A Nephropathy (IgAN) in Greece
Sep 9, 2025, 16:22 PM -
Real-life-Persistence to Antifibrotic Treatments in the French Population
Sep 9, 2025, 16:22 PM -
Methodological Insights From Recent PBAC Recommendations to Support Biosimilar Reimbursement in Australia
Sep 9, 2025, 16:22 PM -
Impact of Mucus Plugs on the Health Economic Burden in Chronic Obstructive Pulmonary Disease (COPD) Patients
Sep 9, 2025, 16:22 PM -
Investigating the Patient-Relevance of Achieving Blood Phe Thresholds in PKU: Results From an Analysis of the OPAL Study
Sep 9, 2025, 16:22 PM -
Impact of Pharmacist-Led Interventions on Health-Related Quality of Life in Diabetic Patients: Assessment Using EQ-5D Domains and Visual Analog Scale
Sep 9, 2025, 16:22 PM -
Exploring Quality of Life in Duchenne Muscular Dystrophy: Insights From Qualitative Patient and Caregiver Interviews
Sep 9, 2025, 16:22 PM -
Indirect Treatment Comparisons in Health Technology Assessment Submissions: A Review and Critique of Best Practice
Sep 9, 2025, 16:22 PM -
Patient-Relevant Benefits From Ixekizumab Treatment in Patients With Psoriasis: Data From the German National Psoriasis Registry PsoBest
Sep 9, 2025, 16:22 PM -
Describing the Burden of Transthyretin Amyloid Cardiomyopathy (ATTR-CM) on Patients and Their Caregivers: A Real-World Survey in Europe, the United States, and Japan
Sep 9, 2025, 16:22 PM -
Real-World Characterization of Urticaria Subtypes in Brazil: A TriNetX-Based Analysis of Demographics, Comorbidities, Treatments, and Laboratory Markers
Sep 9, 2025, 16:22 PM -
Cost Implications of Declining MMR Coverage in England: Modeling NHS Burden and the Value of Catch-Up Vaccination
Sep 9, 2025, 16:22 PM -
Orphan Drug Approvals in the US and Europe: A 2-Year Comparison
Sep 9, 2025, 16:22 PM -
Excel Front-End, R Back-End: A Gateway to Faster Individual Patient Simulations and Probabilistic Sensitivity Analyses in Cost-Effectiveness Models for HTA
Sep 9, 2025, 16:22 PM
